                                                                                                                                     I




                                  113TH CONGRESS
                                     1ST SESSION                        H. R. 1150
                                  To amend the Federal Food, Drug, and Cosmetic Act to preserve the effective-
                                      ness of medically important antimicrobials used in the treatment of
                                      human and animal diseases.




                                                IN THE HOUSE OF REPRESENTATIVES
                                                                MARCH 14, 2013
                                        Ms. SLAUGHTER introduced the following bill; which was referred to the
                                                      Committee on Energy and Commerce




                                                                            A BILL
                                  To amend the Federal Food, Drug, and Cosmetic Act to
                                     preserve the effectiveness of medically important
                                     antimicrobials used in the treatment of human and ani-
                                     mal diseases.
                                    1              Be it enacted by the Senate and House of Representa-
                                    2 tives of the United States of America in Congress assembled,
                                    3     SECTION 1. SHORT TITLE.
                                    4              This Act may be cited as the ‘‘Preservation of Anti-
                                    5 biotics for Medical Treatment Act of 2013’’.
                                    6     SEC. 2. FINDINGS.
                                    7              The Congress finds the following:




                                                                                             2
                                    1                        (1)(A) In 1977, the Food and Drug Adminis-
                                    2              tration concluded that feeding livestock low doses of
                                    3              antibiotics used in human disease treatment could
                                    4              promote the development of antibiotic-resistance in
                                    5              bacteria. However, the Food and Drug Administra-
                                    6              tion did not act in response to these findings, despite
                                    7              laws requiring the agency to do so.
                                    8                        (B) In 2012, the Food and Drug Administra-
                                    9              tion was ordered by a Federal court to address the
                                  10               use of antibiotics in livestock, as the result of a law-
                                  11               suit filed against the agency citing the agency’s fail-
                                  12               ure to act in response to the 1977 findings.
                                  13                         (2)(A) In 1998, the National Academy of
                                  14               Sciences noted that antibiotic-resistant bacteria gen-
                                  15               erate              a        minimum              of        $4,000,000,000               to
                                  16               $5,000,000,000 in costs to United States society
                                  17               and individuals yearly.
                                  18                         (B) In 2009, Cook County Hospital and the Al-
                                  19               liance for Prudent Use of Antibiotics estimated that
                                  20               the total health care cost of antibiotic resistant in-
                                  21               fections               in    the      United            States            was     between
                                  22               $16,600,000,000 and $26,000,000,000 annually.
                                  23                         (3) An April 1999 study by the Government




                                  24               Accountability                 Office          concluded              that        resistant
                                  25               strains of 3 microorganisms that cause food-borne


                                              •HR 1150 IH

                                                                                             3
                                    1              illness            or      disease            in        humans              (Salmonella,
                                    2              Campylobacter, and E. coli) are linked to the use of
                                    3              antibiotics in animals.
                                    4                        (4)(A) Large-scale, voluntary surveys by the
                                    5              Department of Agriculture’s Animal and Plant
                                    6              Health Inspection Service in 1999, 2001, and 2006
                                    7              revealed that—
                                    8                                 (i) 84 percent of grower-finisher swine
                                    9                        farms, 83 percent of cattle feedlots, and 84 per-
                                  10                         cent of sheep farms administer antimicrobials
                                  11                         in the feed or water for health or growth pro-
                                  12                         motion reasons; and
                                  13                                  (ii) many of the antimicrobials identified
                                  14                         are identical or closely related to drugs used in
                                  15                         human            medicine,                  including            tetracyclines,
                                  16                         macrolides,                Bacitracin,                 penicillins,        and
                                  17                         sulfonamides; and
                                  18                         (B) these drugs are used in people to treat seri-
                                  19               ous diseases such as pneumonia, scarlet fever, rheu-
                                  20               matic fever, sexually transmitted infections, skin in-
                                  21               fections, and even pandemics like malaria and
                                  22               plague, as well as bioterrorism agents like smallpox
                                  23               and anthrax.





                                              •HR 1150 IH

                                                                                             4
                                    1                        (5)(A) Any overuse or misuse of antibiotics con-
                                    2              tributes to the spread of antibiotic resistance, wheth-
                                    3              er in human medicine or in agriculture.
                                    4                        (B) Recognizing the public health threat caused
                                    5              by antibiotic resistance, Congress took several steps
                                    6              to curb antibiotic overuse in human medicine
                                    7              through amendments to the Public Health Service
                                    8              Act (42 U.S.C. 201 et seq.) made by section 102 of
                                    9              the Public Health Threats and Emergencies Act
                                  10               (Public Law 106–505, title I; 114 Stat. 2315), but
                                  11               has not yet addressed antibiotic overuse in agri-
                                  12               culture.
                                  13                         (6) In January 2001, a Federal interagency
                                  14               task force—
                                  15                                  (A) released an action plan to address the
                                  16                         continuing decline in effectiveness of antibiotics
                                  17                         against common bacterial infections, referred to
                                  18                         as antibiotic resistance;
                                  19                                  (B) determined that antibiotic resistance is
                                  20                         a growing menace to all people and poses a se-
                                  21                         rious threat to public health; and
                                  22                                  (C) cautioned that if current trends con-
                                  23                         tinue, treatments for common infections will be-




                                  24                         come increasingly limited and expensive, and, in
                                  25                         some cases, nonexistent.


                                              •HR 1150 IH

                                                                                             5
                                    1                        (7) The United States Geological Survey re-
                                    2              ported in March 2002 that—
                                    3                                 (A) antibiotics were present in 48 percent
                                    4                        of the streams tested nationwide; and
                                    5                                 (B) almost half of the tested streams were
                                    6                        downstream from agricultural operations.
                                    7                        (8) The peer-reviewed journal ‘‘Clinical Infec-
                                    8              tious Diseases’’ published a report in June 2002
                                  109              that—            (A) was based on a 2-year review by ex-
                                  11                         perts in human and veterinary medicine, public
                                  12                         health, microbiology, biostatistics, and risk
                                  13                         analysis, of more than 500 scientific studies on
                                  14                         the human health impacts of antimicrobial use
                                  15                         in agriculture; and
                                  16                                  (B)         recommended                   that          antimicrobial
                                  17                         agents should no longer be used in agriculture
                                  18                         in the absence of disease, but should be limited
                                  19                         to therapy for diseased individual animals and
                                  20                         prophylaxis when disease is documented in a
                                  21                         herd or flock.
                                  22                         (9) In a March 2003 report, the National Acad-
                                  23               emy of Sciences stated that—





                                              •HR 1150 IH

                                                                                             6
                                    1                                 (A) a decrease in antimicrobial use in
                                    2                        human medicine alone will have little effect on
                                    3                        the current situation; and
                                    4                                 (B) substantial efforts must be made to
                                    5                        decrease inappropriate overuse in animals and
                                    6                        agriculture.
                                    7                        (10) The Federal Food, Drug, and Cosmetic
                                    8              Act (21 U.S.C. 301 et seq.)—
                                    9                                 (A) requires that all drugs be shown to be
                                  10                         safe before the drugs are approved; and
                                  11                                  (B) places the burden on manufacturers to
                                  12                         account for health consequences and prove safe-
                                  13                         ty.
                                  14                         (11)(A) In 2003, the Food and Drug Adminis-
                                  15               tration modified the drug approval process for anti-
                                  16               biotics to recognize the development of resistant bac-
                                  17               teria as an important aspect of safety, but most
                                  18               antibiotics currently used in animal production sys-
                                  19               tems for nontherapeutic purposes were approved be-
                                  20               fore the Food and Drug Administration began con-
                                  21               sidering resistance during the drug-approval process.
                                  22                         (B) The Food and Drug Administration has not
                                  23               established a schedule for reviewing those existing




                                  24               approvals.
                                              •HR 1150 IH

                                                                                             7
                                    1                        (12)(A) In an April 2004 report, the Govern-
                                    2              ment Accountability Office—
                                    3                                 (i) concluded that Federal agencies do not
                                    4                        collect the critical data on antibiotic use in ani-
                                    5                        mals that they need to support research on
                                    6                        human health risks; and
                                    7                                 (ii) recommended that the Department of
                                    8                        Agriculture and the Department of Health and
                                    9                        Human Services develop and implement a plan
                                  10                         to collect data on antibiotic use in animals.
                                  11                         (B) In a September 2011 update to that report,
                                  12               the Government Accountability Office—
                                  13                                  (i) concluded that Federal agencies had
                                  14                         made limited progress in addressing antibiotic
                                  15                         use in animals;
                                  16                                  (ii) recommended that Federal agencies
                                  17                         fund research on alternatives to current anti-
                                  18                         biotic use practices; and
                                  19                                  (iii) recommended that Federal agencies
                                  20                         track the effectiveness of policies that curb anti-
                                  21                         biotic resistance, including FDA’s voluntary
                                  22                         guidelines reducing antibiotic use in food ani-
                                  23                         mals.





                                  24                         (13) In 2009, the Congressional Research Serv-
                                  25               ice concluded that without restrictions on the use of


                                              •HR 1150 IH

                                                                                             8
                                    1              antimicrobial drugs in the production of livestock,
                                    2              export markets for livestock and poultry could be
                                    3              negatively impacted due to restrictions on the use of
                                    4              antibiotics in other nations.
                                    5                        (14) In 2010, the peer-reviewed journal ‘‘Molec-
                                    6              ular Cell’’ published a study demonstrating that low-
                                    7              dosage use of antibiotics causes a dramatic increase
                                    8              in genetic mutation, raising new concerns about the
                                    9              agricultural practice of using low-dosage antibiotics
                                  10               in order to stimulate growth promotion and rou-
                                  11               tinely prevent disease in unhealthy conditions.
                                  12                         (15) In 2010, the Danish Veterinary and Food
                                  13               Administration testified that the Danish ban of the
                                  14               nontherapeutic use of antibiotics in food animal pro-
                                  15               duction resulted in a marked reduction in anti-
                                  16               microbial resistance in multiple bacterial species, in-
                                  17               cluding Campylobacter and Enterococci.
                                  18                         (16) In 2011, the Food and Drug Administra-
                                  19               tion determined that—
                                  20                                  (A) 13.5 million kilograms of antibacterial
                                  21                         drugs were sold for use on food animals in the
                                  22                         United States in 2010;
                                  23                                  (B) 3.3 million kilograms of antibacterial




                                  24                         drugs were used for human health in 2010; and
                                              •HR 1150 IH

                                                                                             9
                                    1                                 (C) therefore, 80 percent of antibacterial
                                    2                        drugs disseminated in the United States in
                                    3                        2010 were sold for use on food animals, rather
                                    4                        than being used for human health.
                                    5                        (17) In 2011, a review of all scientific studies
                                    6              on antimicrobial use in farm animals, published in
                                    7              Clinical Microbiology Reviews, found that—
                                    8                                 (A) use of antibiotics in food animals leads
                                    9                        to development of reservoirs of antibiotic resist-
                                  10                         ance;
                                  11                                  (B) a ban on antibiotic use in food animals
                                  12                         would preserve their use for medicine; and
                                  13                                  (C) a Danish ban on antibiotics in food
                                  14                         animals resulted in little change in animal mor-
                                  15                         bidity and mortality, and only a modest in-
                                  16                         crease in production cost.
                                  17                         (18) In April 2012, the Food and Drug Admin-
                                  18               istration issued voluntary guidance to industry on
                                  19               reducing antibiotic use in livestock and poultry. As
                                  20               part of that guidance, it summarized over 35 years
                                  21               of peer-reviewed scientific literature regarding use of
                                  22               antimicrobial drugs in livestock. As a result, FDA
                                  23               stated strategies for controlling antibiotic resistance




                                  24               are needed, and are seeking voluntarily limits on an-
                                  25               tibiotic use.


                                              •HR 1150 IH

                                                                                         10
                                    1                        (19)(A) In January 2013, Consumer Reports
                                    2              published test results on pork products bought in
                                    3              grocery stores nationwide showing disturbingly high
                                    4              levels of Salmonella and Yersinia enterocolitica bac-
                                    5              teria that were resistant to the antibiotics used to
                                    6              treat food borne illnesses. A 2003 Consumer Report
                                    7              study showed similar results in poultry products.
                                    8                        (B) The Food and Drug Administration’s Na-
                                    9              tional Antimicrobial Resistance Monitoring System
                                  10               routinely finds that retail meat products are con-
                                  11               taminated with bacteria (including the foodborne
                                  12               pathogens Campylobacter and Salmonella) that are
                                  13               resistant to antibiotics important in human medi-
                                  14               cine. The 2011 National Antimicrobial Resistance
                                  15               Monitoring System report found that the percentage
                                  16               of meat containing antibiotic resistant bacteria in-
                                  17               creases each year and that many of these bacteria
                                  18               exhibit multiple antibiotic resistance.
                                  19                         (20) Antibiotic resistance, resulting in a re-
                                  20               duced number of effective antibiotics, may signifi-
                                  21               cantly impair the ability of the United States to re-
                                  22               spond to terrorist attacks involving bacterial infec-
                                  23               tions or a large influx of hospitalized patients.





                                  24                         (21) Many scientific studies confirm that the
                                  25               nontherapeutic use of antibiotics in agricultural ani-


                                              •HR 1150 IH

                                                                                         11
                                    1              mals contribute to the development of antibiotic-re-
                                    2              sistant bacterial infections in people.
                                    3                        (22) Epidemiological research has shown that
                                    4              resistant Salmonella and Campylobacter infections
                                    5              are associated with increased numbers of ill patients
                                    6              and bloodstream infections, and increased death.
                                    7                        (23) The American Medical Association, the
                                    8              American Public Health Association, the National
                                    9              Association of County and City Health Officials, and
                                  10               the National Sustainable Agriculture Coalition are
                                  11               among the over 400 organizations representing
                                  12               health, consumer, agricultural, environmental, hu-
                                  13               mane, and other interests that have supported enact-
                                  14               ment of legislation to phase out nontherapeutic use
                                  15               in         farm          animals              of         medically                important
                                  16               antimicrobials.
                                  17      SEC. 3. PURPOSE.
                                  18               The purpose of this Act is to preserve the effective-
                                  19 ness of medically important antimicrobials used in the
                                  20 treatment of human and animal diseases.
                                  21      SEC. 4. PROOF OF SAFETY OF MEDICALLY IMPORTANT
                                  22                              ANTIMICROBIALS.
                                  23               (a) APPLICATIONS PENDING                                OR    SUBMITTED AFTER
                                  24 ENACTMENT.—Section 512(d)(1) of the Federal Food,




                                              •HR 1150 IH

                                                                                         12
                                    1 Drug, and Cosmetic Act (21 U.S.C. 360b(d)(1)) is amend-
                                    2 ed—
                                    3                        (1) in the first sentence—
                                    4                                 (A) in subparagraph (H), by striking ‘‘or’’
                                    5                        at the end;
                                    6                                 (B) in subparagraph (I), by inserting ‘‘or’’
                                    7                        at the end; and
                                    8                                 (C) by inserting after subparagraph (I) the
                                    9                        following:
                                  10                                  ‘‘(J) with respect to a medically important
                                  11                         antimicrobial (as defined in subsection (q)), the
                                  12                         applicant has failed to demonstrate that there
                                  13                         is a reasonable certainty of no harm to human
                                  14                         health due to the development of antimicrobial
                                  15                         resistance that is attributable, in whole or in
                                  16                         part, to the nontherapeutic use (as defined in
                                  17                         subsection (q)) of the medically important anti-
                                  18                         microbial or drug;’’; and
                                  19                         (2) in the second sentence, by striking ‘‘(A)
                                  20               through (I)’’ and inserting ‘‘(A) through (J)’’.
                                  21               (b) PHASED ELIMINATION                                  OF      NONTHERAPEUTIC
                                  22 USE                   IN     ANIMALS               OF          MEDICALLY                   IMPORTANT
                                  23 ANTIMICROBIALS.—Section 512 of the Federal Food,




                                  24 Drug, and Cosmetic Act (21 U.S.C. 360b) is amended by
                                  25 adding at the end the following:


                                              •HR 1150 IH

                                    1              ‘‘(q) PHASED ELIMINATION          13                     OF     NONTHERAPEUTIC
                                    2 USE                  IN     ANIMALS               OF          MEDICALLY                   IMPORTANT
                                    3 ANTIMICROBIALS.—
                                    4                        ‘‘(1) APPLICABILITY.—This paragraph applies
                                    5              to the nontherapeutic use in a food-producing ani-
                                    6              mal of a drug—
                                    7                                 ‘‘(A) that is a medically important anti-
                                    8                        microbial; or
                                    9                                 ‘‘(B)(i) for which there is in effect an ap-
                                  10                         proval of an application or an exemption under
                                  11                         subsection (b), (i), or (j) of section 505; or
                                  12                                  ‘‘(ii) that is otherwise marketed for human
                                  13                         use.
                                  14                         ‘‘(2) WITHDRAWAL.—The Secretary shall with-
                                  15               draw the approval of a nontherapeutic use in food-
                                  16               producing animals of a drug described in paragraph
                                  17               (1) on the date that is 2 years after the date of en-
                                  18               actment of this subsection unless—
                                  19                                  ‘‘(A) before the date that is 2 years after
                                  20                         the date of the enactment of this subsection,
                                  21                         the Secretary makes a final written determina-
                                  22                         tion that the holder of the approved application
                                  23                         has demonstrated that there is a reasonable




                                  24                         certainty of no harm to human health due to
                                  25                         the development of antimicrobial resistance that


                                              •HR 1150 IH

                                                                                         14
                                    1                        is attributable in whole or in part to the non-
                                    2                        therapeutic use of the drug; or
                                    3                                 ‘‘(B) before the date specified in subpara-
                                    4                        graph (A), the Secretary makes a final written
                                    5                        determination under this subsection, with re-
                                    6                        spect to a risk analysis of the drug conducted
                                    7                        by the Secretary and other relevant informa-
                                    8                        tion, that there is a reasonable certainty of no
                                    9                        harm to human health due to the development
                                  10                         of antimicrobial resistance that is attributable
                                  11                         in whole or in part to the nontherapeutic use of
                                  12                         the drug.
                                  13                         ‘‘(3) EXEMPTIONS.—Except as provided in
                                  14               paragraph (5), if the Secretary grants an exemption
                                  15               under section 505(i) for a drug that is a medically
                                  16               important antimicrobial, the Secretary shall rescind
                                  17               each approval of a nontherapeutic use in a food-pro-
                                  18               ducing animal of the medically important anti-
                                  19               microbial, as of the date that is 2 years after the
                                  20               date on which the Secretary grants the exemption.
                                  21                         ‘‘(4) APPROVALS.—Except as provided in para-
                                  22               graph (5), if an application for a drug that is a
                                  23               medically important antimicrobial is submitted to




                                  24               the Secretary under section 505(b), the Secretary
                                  25               shall rescind each approval of a nontherapeutic use


                                              •HR 1150 IH

                                                                                         15
                                    1              in a food-producing animal of the medically impor-
                                    2              tant antimicrobial, as of the date that is 2 years
                                    3              after the date on which the application is submitted
                                    4              to the Secretary.
                                    5                        ‘‘(5) EXCEPTIONS.—Paragraph (3) or (4), as
                                    6              the case may be, shall not apply if—
                                    7                                 ‘‘(A) before the date on which approval
                                    8                        would be rescinded under that paragraph, the
                                    9                        Secretary makes a final written determination
                                  10                         that the holder of the application for the ap-
                                  11                         proved nontherapeutic use has demonstrated
                                  12                         that there is a reasonable certainty of no harm
                                  13                         to human health due to the development of
                                  14                         antimicrobial resistance that is attributable in
                                  15                         whole or in part to the nontherapeutic use in
                                  16                         the food-producing animal of the medically im-
                                  17                         portant antimicrobial; or
                                  18                                  ‘‘(B) before the date specified in subpara-
                                  19                         graph (A), the Secretary makes a final written
                                  20                         determination, with respect to a risk analysis of
                                  21                         the medically important antimicrobial conducted
                                  22                         by the Secretary and any other relevant infor-
                                  23                         mation, that there is a reasonable certainty of




                                  24                         no harm to human health due to the develop-
                                  25                         ment of antimicrobial resistance that is attrib-


                                              •HR 1150 IH

                                                                                         16
                                    1                        utable in whole or in part to the nontherapeutic
                                    2                        use of the medically important antimicrobial.
                                    3                        ‘‘(6) DEFINITION.—In this subsection:
                                    4                                 ‘‘(A) The term ‘medically important anti-
                                    5                        microbial’ means a drug that—
                                    6                                        ‘‘(i) is intended for use in food-pro-
                                    7                                 ducing animals; and
                                    8                                        ‘‘(ii) is composed wholly or partly of—
                                    9                                                  ‘‘(I) any kind of penicillin, tetra-
                                  10                                         cycline,               macrolide,                 lincosamide,
                                  11                                         streptogramin,                   aminoglycoside,          sul-
                                  12                                         fonamide, or cephalosporin; or
                                  13                                                   ‘‘(II) a drug from an anti-
                                  14                                         microbial class that is listed as ‘highly
                                  15                                         important’, ‘critically important’, or
                                  16                                         ‘important’ by the World Health Or-
                                  17                                         ganization in the latest edition of its
                                  18                                         publication entitled ‘Critically Impor-
                                  19                                         tant Antimicrobials for Human Medi-
                                  20                                         cine’ (or a successor publication).
                                  21                                  ‘‘(B) The term ‘therapeutic use’, with re-
                                  22                         spect to a medically important antimicrobial,
                                  23                         means the use of antimicrobials for the specific




                                  24                         purpose of treating an animal with a docu-
                                  25                         mented disease or infection. Such term does not


                                              •HR 1150 IH

                                                                                         17
                                    1                        include the continued use of such an anti-
                                    2                        microbial in the animal after the disease or in-
                                    3                        fection is resolved.
                                    4                                 ‘‘(C) The term ‘nontherapeutic use’—
                                    5                                         ‘‘(i) means administration of anti-
                                    6                                 biotics to an animal through feed and
                                    7                                 water (or, in poultry hatcheries, through
                                    8                                 any means) for purposes (such as growth
                                    9                                 promotion, feed efficiency, weight gain, or
                                  10                                  disease prevention) other than therapeutic
                                  11                                  use or nonroutine disease control; and
                                  12                                          ‘‘(ii) includes any repeated or regular
                                  13                                  pattern of use of medically important
                                  14                                  antimicrobials for purposes other than
                                  15                                  therapeutic use or nonroutine disease con-
                                  16                                  trol.
                                  17                                  ‘‘(D) The term ‘noncustomary situation’
                                  18                         does not include normal or standard practice
                                  19                         and conditions on the premises that facilitate
                                  20                         the transmission of disease.
                                  21                                  ‘‘(E) The term ‘nonroutine disease control’
                                  22                         means the use of antibiotics on an animal that
                                  23                         is not sick but where it can be shown that a




                                  24                         particular disease or infection is present, or is
                                  25                         likely to occur because of a specific, noncus-


                                              •HR 1150 IH

                                                                                         18
                                    1                        tomary situation, on the premises at the barn,
                                    2                        house, pen, or other level at which the animal
                                    3                        is kept.’’.
                                    4     SEC. 5. LIMITATIONS ON USE OF MEDICALLY IMPORTANT
                                    5                             ANTIMICROBIALS FOR NONROUTINE DISEASE
                                    6                             CONTROL.

                                    7              (a) PROHIBITED ACTS.—Section 301 of the Federal
                                    8 Food, Drug, and Cosmetic Act (21 U.S.C. 331) is amend-
                                    9 ed by adding at the end the following:
                                  10               ‘‘(ccc) The administration of a medically important
                                  11 antimicrobial to a food-producing animal for nonroutine
                                  12 disease control in violation of the requirements of section
                                  13 512A.’’.
                                  14               (b) REQUIREMENTS.—Chapter V of the Federal
                                  15 Food, Drug, and Cosmetic Act is amended by inserting
                                  16 after section 512 of such Act (21 U.S.C. 360b) the fol-
                                  17 lowing:
                                  18      ‘‘SEC. 512A. LIMITATIONS ON USE OF MEDICALLY IMPOR-
                                  19                              TANT ANTIMICROBIALS FOR NONROUTINE
                                  20                              DISEASE CONTROL.

                                  21               ‘‘(a) PROHIBITION.—It shall be unlawful to admin-
                                  22 ister (including by means of animal feed) a medically im-
                                  23 portant antimicrobial to a food-producing animal for non-




                                  24 routine disease control unless—
                                              •HR 1150 IH

                                                                                         19
                                    1                        ‘‘(1) there is a significant risk that a disease or
                                    2              infection present on the premises will be transmitted
                                    3              to the food-producing animal;
                                    4                        ‘‘(2) the administration of the medically impor-
                                    5              tant antimicrobial to the food-producing animal is
                                    6              necessary to prevent or reduce the risk of trans-
                                    7              mission of the disease or infection described in para-
                                    8              graph (1);
                                    9                        ‘‘(3) the medically important antimicrobial is
                                  10               administered to the food-producing animal for non-
                                  11               routine disease control for the shortest duration pos-
                                  12               sible to prevent or reduce the risk of transmission of
                                  13               the disease or infection described in paragraph (1)
                                  14               to the animal; and
                                  15                         ‘‘(4) the medically important antimicrobial is
                                  16               administered—
                                  17                                  ‘‘(A) at a scale no greater than the barn,
                                  18                         house, or pen level; and
                                  19                                  ‘‘(B) to the fewest animals possible to pre-
                                  20                         vent or reduce the risk of transmission of the
                                  21                         disease or infection described in paragraph (1).
                                  22               ‘‘(b) DEFINITIONS.—In this section:
                                  23                         ‘‘(1) The term ‘food-producing animal’ means a




                                  24               food-producing animal intended for sale in interstate
                                  25               commerce.


                                              •HR 1150 IH

                                                                                         20
                                    1                        ‘‘(2) The terms ‘medically important anti-
                                    2              microbial’ and ‘nonroutine disease control’ have the
                                    3              meanings given to such terms in section 512(q).’’.
                                    4              (c) APPLICABILITY.—The amendments made by this
                                    5 section apply beginning on the date that is 6 months after
                                    6 the date of the enactment of this Act.
                                              •HR 1150 IH                                  Æ
